

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 August 2012 (16.08.2012)



(10) International Publication Number
WO 2012/109605 A8

(51) International Patent Classification:

A61K 31/4375 (2006.01) A61K 9/28 (2006.01)
C07D 498/22 (2006.01) A61P 1/00 (2006.01)

(21) International Application Number:

PCT/US2012/024746

(22) International Filing Date:

10 February 2012 (10.02.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/441,902	11 February 2011 (11.02.2011)	US
61/530,905	18 October 2011 (18.10.2011)	US
61/556,649	7 November 2011 (07.11.2011)	US
61/583,024	4 January 2012 (04.01.2012)	US

(71) Applicant (for all designated States except US): **SALIX PHARMACEUTICALS, LTD.** [US/US]; 8510 Colonnade Center Drive, Raleigh, NC 27615 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **PARENT, Stephan** [US/US]; 2120 Cumulus Ct, West Lafayette, IN 47906

(US). **McQUEEN, Lisa** [US/US]; 3472 Tunbridge Way, West Lafayette, IN 47906 (US). **ANDRES, Patricia** [US/US]; 2307 Sycamore Lane, West Lafayette, IN 47906 (US). **SCHIELDS, Paul** [US/US]; 4203 Peterborough, West Lafayette, IN 47906 (US). **WU, Yiduo** [CN/US]; 947B Village Drive East, North Brunswick, NJ 08902 (US). **DING, Fei** [US/US]; 7575 West 106th Street, Apartment 370, Overland Park, KS 66212 (US). **SMIT, Jared P.** [US/US]; 4509 McCarty Lane, Lafayette, Indiana 47905 (US).


(74) Agents: **SPARKS, Jonathan, M.** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: FORMS OF RIFAXIMIN AND USES THEREOF

Figure 1. Representative XRPD patterns of rifaximin Form μ .



(57) Abstract: Embodiments relate to Rifaximin polymorphic, salt, and hydrate forms, methods of producing polymorphic forms and to their use in medicinal preparations and to therapeutic methods using them.



(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

(48) Date of publication of this corrected version:

22 November 2012

(15) Information about Correction:

see Notice of 22 November 2012